三种即时核酸检测方法在儿童流感A/B病毒检测中的性能比较
该前瞻性研究纳入201例18岁以下儿童鼻咽拭子标本,以CDC流感A/B PCR为参考方法,比较ID Now、Cobas LIAT和Xpert Xpress Flu三种CLIA豁免的即时分子检测对流感A/B病毒的检测性能。结果显示三种方法对流感A病毒和B病毒的总体敏感性相当,所有方法特异性均>97%,且敏感性高于历史BD Veritor抗原检测。
要点
- 三种即时分子检测对流感A和B病毒的敏感性总体相当,特异性均>97%。
- ID Now对流感A病毒敏感性93.2%,对B病毒97.2%;LIAT对A病毒100%,对B病毒94.4%;Xpert对A病毒100%,对B病毒91.7%。
- 三种分子检测敏感性均高于历史BD Veritor抗原检测(A病毒79.5%,B病毒66.7%)。
核心结论
- ID Now、LIAT和Xpert三种即时分子检测对儿童流感A/B病毒检测性能相当,敏感性高于传统抗原检测。
研究设计与样本
- 前瞻性研究,2018年1月至4月纳入201例18岁以下儿童,采集鼻咽拭子标本,以CDC流感A/B PCR为参考方法比较三种CLIA豁免的即时分子检测。
主要发现
- CDC PCR检出流感A/B病毒107例(A病毒73例,B病毒36例,A/B双阳性2例)。
- ID Now检出102例(A病毒69例,B病毒37例,双阳性4例),无效结果1/201(0.5%)。
- LIAT检出112例(A病毒74例,B病毒38例),无效结果11/201(5.5%)。
- Xpert检出112例(A病毒76例,B病毒36例),无效结果6/201(3.0%)。
- 三种方法对流感A病毒敏感性分别为ID Now 93.2%、LIAT 100%、Xpert 100%;对B病毒敏感性分别为97.2%、94.4%、91.7%;所有方法特异性均>97%。
关键数值与推荐
- ID Now对流感A病毒敏感性93.2%,对B病毒97.2%;LIAT对A病毒100%,对B病毒94.4%;Xpert对A病毒100%,对B病毒91.7%。
- 所有方法对流感A和B病毒检测特异性均>97%。
- 历史BD Veritor抗原检测敏感性:流感A病毒79.5%,流感B病毒66.7%。
临床怎么用
- 三种即时分子检测均可用于儿童流感A/B病毒的快速诊断,敏感性高于传统抗原检测。
局限性
- 标本冷冻后分批检测可能影响性能评估;参考方法为CDC PCR,但未报告与商业PCR的比对。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Early diagnosis of influenza (Flu) is critical for patient management and infection control. The ID Now influenza A & B 2 (ID Now) assay (Abbott Laboratories), Cobas influenza A/B nucleic acid test (LIAT; Roche Molecular Systems, Inc.), and Xpert Xpress Flu (Xpert; Cepheid) are rapid, point-of-care molecular assays for Flu virus detection. The study aim was to compare the performances of these three commercially available Clinical Laboratory Improvement Amendments (CLIA)-waived Flu virus assays. We prospectively enrolled 201 children <18 years old from January to April 2018 and collected nasopharyngeal swab specimens in viral medium. Aliquots were frozen for testing on different diagnostic platforms, as per the manufacturers' instructions. CDC Flu A/B PCR was used as a reference method to evaluate the performances of these three platforms. Among the 201 specimens tested, the CDC Flu A/B PCR assay detected Flu A/B virus in 107 samples (Flu A virus, 73 samples; Flu B virus, 36 samples; dual Flu A/B virus positive, 2 samples), while the ID Now virus detected 102 samples (Flu A virus, 69 samples; Flu B virus, 37 samples; dual Flu A/B virus positive, 4 samples; invalid rate, 1/201 [0.5%]), the LIAT detected 112 samples (Flu A virus, 74 samples; Flu B virus, 38 samples; invalid rate, 11/201 [5.5%]), and the Xpert assay detected 112 samples (Flu A virus, 76 samples; Flu B virus, 36 samples; invalid rate, 6/201 [3.0%]). The overall sensitivities for the ID Now assay, LIAT, and Xpert assay for Flu A virus detection (93.2%, 100%, and 100%, respectively) and Flu B virus detection (97.2%, 94.4%, and 91.7%, respectively) were comparable. The specificity for Flu A and B virus detection by all methods was >97%. These molecular assays had higher sensitivity than did a historical standard-of-care test from the BD Veritor antigen test (Flu A virus, 79.5%; Flu B virus, 66.7%).
引用
- Kanwar N, Michael J, Doran K, et al. Comparison of the ID Now Influenza A & B 2, Cobas Influenza A/B, and Xpert Xpress Flu Point-of-Care Nucleic Acid Amplification Tests for Influenza A/B Virus Detection in Children. J Clin Microbiol. 2020. PMID: 31941689. doi:10.1128/JCM.01611-19
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。